Plus: insulin biosimilar approved; glycemic control to reduce Parkinson's; SGLT2 inhibitors for kidney disease
Tuesday, Sept. 1, 2020 : Issue #1059 DISASTERS AVERTED — Near Miss Case Studies
SGLT2 Inhibitors for Kidney Disease |
|
Letter from the Editor
Melinda Rodriguez, PharmD Candidate 2021, Lake Erie College of Osteopathic Medicine, is attempting to help us understand the concept of Biosimilars. Her drug class of choice to unravel the process is insulin. In her feature this week she looks at the radical changes the FDA has to make to allow the almost, but not quite, duplication of the branded product.
As this trend continues, it will be interesting to see if lower insulin prices will become the norm, or will PBM’s keep these products off formularies so they can get their branded rebates?
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
| |
|
|
|
DISASTERS AVERTED — Near Miss Case Studies |
|
| SGLT2 Inhibitors for Kidney Disease
A 56-year old male with type 2 diabetes and stage 3 chronic kidney disease contacted us recently regarding his new prescription for the SGLT2 inhibitor canagliflozin (Invokana).... |
| |
|
|
TOP STORIES - Diabetes News and Research |
|
| |
|
|
|
| | | | About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com |
|
|
|
|
| | |
|
|
|
|
